Fondo · Feb 2026
External launch coverage says Reticular helps pharma companies steer protein models using mechanistic interpretability and highlights GFP steering as a proof of concept.
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
YC-backed biotechnology company focused on IVF genetic screening and polygenic embryo risk reports from existing PGT data; it also publishes mechanistic-interpretability research for protein-language models. I did not find a public careers page or X account in the reviewed sources.
Primary product
Embryo genetic screening and IVF risk reports (Pregnancy Loss Panel, Embryo Core, Embryo Complete)
Founded
2024
Headquarters
San Francisco, CA, United States
Team size
2-10 employees
Industry
Biotechnology Research
Sub-industry
Reproductive genetics / IVF embryo analysis
Offices
San Francisco, CA, United States (717 California St, San Francisco, CA 94108)
Open Positions
0 jobs at Reticular
No open positions
Check back later for new openings